Assessing Regenxbio: Insights From 4 Financial Analysts
Portfolio Pulse from Benzinga Insights
Regenxbio (NASDAQ:RGNX) has received mixed ratings from 4 analysts, all of whom are bullish. The average 12-month price target has increased to $38.00, with a high of $40.00 and a low of $36.00. Despite facing revenue growth challenges, Regenxbio's net margin, ROE, and ROA surpass industry standards, although it has a higher debt-to-equity ratio.
June 07, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regenxbio has received bullish ratings from 4 analysts, with an average 12-month price target of $38.00. The company's net margin, ROE, and ROA are strong, but it faces revenue growth challenges and has a higher debt-to-equity ratio.
The unanimous bullish ratings from analysts and the increase in the average price target to $38.00 suggest positive sentiment. However, the company's revenue decline and high debt-to-equity ratio present challenges. The strong net margin, ROE, and ROA indicate good financial management, which could support the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100